Maytansinoid DM4

Cat. No.: HY-100503: FAQs
Data Sheet Handling Instructions

Molarity Calculator

Maytansinoid DM4 is a thiol-containing maytansine derivative with highly potent cytotoxicity. Maytansinoid DM4 can be used as a cytotoxic moiety of ADC.

For research use only. We do not sell to patients.

Maytansinoid DM4 Chemical Structure

CAS No. : 799840-96-3

Size	Price	Stock
5 mg		Ask For Quote & Lead Time
10 mg		Ask For Quote & Lead Time
25 mg		Ask For Quote & Lead Time

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of Maytansinoid DM4:

DM4 In-stock

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All ADC Cytotoxin Isoform Specific Products:

View All Isoforms

Auristatin Calicheamicins Camptothecins Daunorubicins/Doxorubicins Duocarmycins Maytansinoids Pyrrolobenzodiazepines Traditional Cytotoxic Agents

Biological Activity
Purity & Documentation
References
Customer Review

Description

Maytansinoid DM4 is a thiol-containing maytansine derivative with highly potent cytotoxicity. Maytansinoid DM4 can be used as a cytotoxic moiety of ADC^[1]^[2].

IC₅₀ & Target^[1]^[2]

Maytansinoids

In Vitro

Maytansine is a natural benzoansamacrolide product isolated from the bark of the African shrub Maytenus ovatus. Maytansine binds to the same site on tubulin as the vinca alkaloids, with similar in vitro inhibition constants, but is a more-potent cytotoxin^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

794.39

Formula

C₃₉H₅₆ClN₃O₁₀S

CAS No.

799840-96-3

SMILES

C[C@]1([C@H](CC(N(C(C=C(C2)C=C3OC)=C3Cl)C)=O)OC([C@H](C)N(C)C(CCC(C)(S)C)=O)=O)[C@@](C(C)([C@](OC4=O)([H])C[C@]([C@@H](/C=C/C=C2\C)OC)(N4)O)C)([H])O1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337. [Content Brief]

[2]. Zhao RY, et al. Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates. J Med Chem. 2011 May 26;54(10):3606-23. [Content Brief]